ibalizumab (97)(59)							

Structure	

Ig ?4- heavy chain / Chaine lourde Ig ?4 / Cadena pesada Ig ?4

QVQLQQSGPE  VVKPGASVKM  SCKASGYTFT  SYVIHWVRQK  PGQGLDWIGY  50 

INPYNDGTDY  DEKFKGKATL  TSDTSTSTAY  MELSSLRSED  TAVYYCAREK  100 

DNYATGAWFA  YWGQGTLVTV  SSASTKGPSV  FPLAPCSRST  SESTAALGCL  150

VKDYFPEPVT  VSWNSGALTS  GVHTFPAVLQ  SSGLYSLSSV  VTVPSSSLGT  200 

KTYTCNVDHK  PSNTKVDKRV  ESKYGPPCPS  CPAPEFLGGP  SVFLFPPKPK  250 

DTLMISRTPE  VTCVVVDVSQ  EDPEVQFNWY  VDGVEVHNAK  TKPREEQFNS  300 

TYRVVSVLTV  LHQDWLNGKE  YKCKVSNKGL  PSSIEKTISK  AKGQPREPQV  350 

YTLPPSQEEM  TKNQVSLTCL  VKGFYPSDIA  VEWESNGQPE  NNYKTTPPVL  400 

DSDGSFFLYS  RLTVDKSRWQ  EGNVFSCSVM  HEALHNHYTQ  KSLSLSLGK   449

?- light chain / Chaine legere Ig ? / Cadena ligera Ig ?

DIVMTQSPDS  LAVSLGERVT  MNCKSSQSLL  YSTNQKNYLA  WYQQKPGQSP  50 

KLLIYWASTR  ESGVPDRFSG  SGSGTDFTLT  ISSVQAEDVA  VYYCQQYYSY  100 

RTFGGGTKLE  IKRTVAAPSV  FIFPPSDEQL  KSGTASVVCL  LNNFYPREAK  150 

VQWKVDNALQ  SGNSQESVTE  QDSKDSTYSL  SSTLTLSKAD  YEKHKVYACE  200 

VTHQGLSSPV  TKSFNRGEC						219

Molecular formula  (Times New Roman 12) 

Description

% hB

/

p

?

+-

v

sh

*

-

k

n

~

?

+-

l

r

o

f

231-231'')-bisdisulfide dimer

	

WHO 

International Nonproprietary Names Programme	

17/05/2007

8818

Page   NUMPAGES  1 



		

